Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Jon Congleton Sells 16,229 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) CEO Jon Congleton sold 16,229 shares of the firm's stock in a transaction on Friday, June 14th. The stock was sold at an average price of $12.52, for a total value of $203,187.08. Following the completion of the transaction, the chief executive officer now directly owns 976,271 shares of the company's stock, valued at $12,222,912.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Jon Congleton also recently made the following trade(s):

• On Wednesday, June 12th, Jon Congleton sold 16,607 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $12.77, for a total value of $212,071.39.

Mineralys Therapeutics Trading Down 0.9 %

Shares of NASDAQ:MLYS traded down $0.11 on Friday, reaching $12.58. 105,832 shares of the company traded hands, compared to its average volume of 154,178. The business's 50-day simple moving average is $12.69 and its 200 day simple moving average is $11.66. Mineralys Therapeutics, Inc. has a 52 week low of $5.85 and a 52 week high of $17.44. The stock has a market capitalization of $624.60 million, a P/E ratio of -5.74 and a beta of 2.03.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.02). Sell-side analysts expect that Mineralys Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MLYS has been the subject of a number of analyst reports. The Goldman Sachs Group initiated coverage on Mineralys Therapeutics in a report on Tuesday, April 2nd. They issued a "buy" rating and a $30.00 price target for the company. Lifesci Capital reiterated an "outperform" rating on shares of Mineralys Therapeutics in a research report on Tuesday, March 26th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. PNC Financial Services Group Inc. grew its stake in shares of Mineralys Therapeutics by 17,821.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,122 shares of the company's stock worth $35,000 after purchasing an additional 4,099 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Mineralys Therapeutics in the fourth quarter worth about $41,000. CWM LLC grew its stake in shares of Mineralys Therapeutics by 120.0% in the fourth quarter. CWM LLC now owns 5,891 shares of the company's stock worth $51,000 after purchasing an additional 3,213 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Mineralys Therapeutics in the fourth quarter worth about $87,000. Finally, CreativeOne Wealth LLC bought a new stake in shares of Mineralys Therapeutics in the fourth quarter worth about $92,000. 84.46% of the stock is owned by institutional investors.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.